Timmerman Report

The Long Run with Luke Timmerman

"The Long Run"Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous. Join ho...

Não deixe de visitar o site do podcast e apoiar quem o produz: soundcloud.com

Autor

Timmerman Report

Categoria

Science

Site do podcast

soundcloud.com

Último episódio

16 de nov de 2026

Onde ouvir?

Podcasts no app Replaio Radio Em breve

Os podcasts estão chegando ao app. Instale agora e seja o primeiro a descobrir um jeito totalmente novo de curtir podcasts

Baixe no Google Play Instale grátis Android 10 mi+ downloads · nota 4,7+ iOS em breve

Episódios

Ep214: Shana Kelley on a Wearable Continuous Immune Monitor 16.11.2026

Shana Kelley, a professor of chemistry at Northwestern University and president of the Chan Zuckerberg Biohub Chicago, on developing a wearable continuous immune monitor.

Ep213: Daphne Koller on The Moment in AI Drug Discovery 03.11.2026

Daphne Koller, founder and CEO of South San Francisco-based Insitro, on the moment in AI drug discovery.

Ep212: Tim Shannon on Creating Targeted Protein Degraders as Medicines 23.10.2026

Tim Shannon is a general partner at Canaan Partners, and a founding executive at a pair of targeted protein degrader companies -- Arvinas and Halda Therapeutics.

Ep211: Ardem Patapoutian on Touch, Pain & New Discoveries in Neuroscience 07.10.2026

Arden Patapoutian, professor of neuroscience at Scripps Research and Howard Hughes Medical Institute, on new discoveries in neuroscience related to our sense of touch, pain, and more.

Ep210: Cameron Turtle on Long-Lasting Antibodies for Immune Disorders 23.09.2026

Cameron Turtle, CEO of Waltham, Mass.-based Spyre Therapeutics, on developing long-lasting antibodies for immune disorders.

Ep209: Mathai Mammen on Developing Drugs Against Undruggable Targets 09.09.2026

Mathai Mammen, CEO of Cambridge, Mass.-based Parabilis Medicine, on developing alpha helical peptide molecules against hard targets of disease.

Ep208: Gary Nabel on Developing a Vaccine for Epstein-Barr Virus 25.08.2026

Gary Nabel, CEO of Weston, Mass.-based ModeX Therapeutics, on developing a vaccine for Epstein-Barr Virus.

Ep207: Jason Coloma on Genetic Medicines for Kidney Diseases 11.08.2026

Jason Coloma, CEO of South San Francisco-based Maze Therapeutics, on developing small molecule drugs based on human genetics for kidney diseases.

Ep206: Lyn Baranowski on Inhalable Medicines for Severe Lung Diseases 28.07.2026

Lyn Baranowski, CEO of Boston-based Avalyn Pharma, on developing inhalable medicines for severe lung diseases.

Ep205: Heather Turner on a Schizophrenia Drug Patients Can Stick With 14.07.2026

Heather Turner, CEO of New York-based LB Pharma, on developing a new schizophrenia drug designed to better cross the blood-brain barrier, be dosed once daily, and make it easier for patients to take long term.

Ep204: Troy Wilson on Precision Cancer Drugs and Combos 30.06.2026

Troy Wilson, CEO of San Diego-based Kura Oncology, on his career in biotech and developing targeted cancer drugs.

Ep203: Sri Kosuri on Small Molecule Correctors of Disease 16.06.2026

Sri Kosuri, co-founder and CEO of Emeryville, Calif.-based Octant Bio, on small molecules designed to correct protein misfolding and mistrafficking at the root of many diseases.

Ep202: Becky Pferdehirt on Reimagining Science for the AI Era 02.06.2026

Becky Pferdehirt, CEO of Emeryville, CA-based Radial, the life sciences unit of Astera Institute, on reimagining biology to take advantage of advances in AI.

Ep201: Jeremy Levin on Biotech in the Balance 19.05.2026

Jeremy Levin, executive chair of Ovid Therapeutics, discusses his new book "Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust."

Ep200: Richard Pops Reflects on a 35-Year Career in Biotech 05.05.2026

Alkermes CEO Richard Pops reflects on his 35-year career leading the company and its new opportunity in orexin biology for sleep disorders and more neurological conditions.

Ep199: Martin Burke on Making Small Molecule Medicines for the AI Era 21.04.2026

Marty Burke, a professor of chemistry at the University of Illinois and co-founder of Excelsior Sciences, on making small molecule synthesis more automated for AI.

Ep198: Abbas Kazimi on Computation and Culture for Drug Discovery 07.04.2026

Abbas Kazimi, CEO of Boston-based Nimbus Therapeutics, on computation and culture for drug discovery.

Ep197: Viswa Colluru on Discovering Drugs Inspired by Mother Nature 31.03.2026

Viswa Colluru, founder and CEO of Boulder, Colo.-based Enveda, on drug discovery with a chemistry platform inspired by natural products.

Ep196: Otello Stampacchia on Europe's Biotech Crisis 17.03.2026

Otello Stampacchia, founder and managing director of Omega Funds, on attempting to reform Europe's biotech investment climate.

Ep195: Ken Song on T-cell Engagers for Autoimmune Diseases 03.03.2026

Ken Song, CEO of San Diego-based Candid Therapeutics, on developing bispecific T-cell engaging antibodies for autoimmune disease.

Ep194: Ansu Satpathy on Cancer and Autoimmune Drug Discovery 17.02.2026

Ep194: Ansu Satpathy on Cancer and Autoimmune Drug Discovery by Timmerman Report

Ep193: Ron Renaud on Helping People Lose Weight With GLP-1 Medicines 22.01.2026

Ron Renaud, CEO of Waltham, Mass.-based Kailera Therapeutics, on developing GLP-1 based medicines to help people lose weight and live healthier lives.

Ep192: Kate Haviland on Following the Science to Precision Immunology 08.01.2026

Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned to a precision immunology company and was acquired by Sanofi for $9.5 billion.

Ep191: Emily Conley on Small Molecules to Correct a Rare Kidney Disease 15.12.2025

Emily Conley, CEO of Berkeley, CA-based Renasant Bio, on developing small molecule correctors and potentiators for autosomal dominant polycystic kidney disease (ADPKD).

Ep190: Neil Kumar on Building a Rare Disease Drug Company 20.11.2025

Neil Kumar is founder and CEO of Palo Alto, Calif.-based BridgeBio Pharma, a rare disease drug developer.

Ouça o podcast The Long Run with Luke Timmerman no Replaio

Rádio e podcasts em um só app - grátis e sem cadastro. Instale hoje e não perca o lançamento

Baixe no Google Play

O Replaio não é o publicador dos podcasts; os nomes dos programas, as capas e o áudio pertencem aos seus autores e são distribuídos por feeds RSS públicos